Items tagged with Treatment
First-of-its-kind global collaboration launched to develop transformative treatment regimens for TB (post)
-- A new global collaboration of philanthropic, non-profit and private sector organizations will work together to accelerate the development of novel TB treatment regimens for all TB patients.
-- The global collaboration aims to create treatment regimens comprised of medicines to which there is limited or no drug resistance and that are ready for phase 3 development.
-- The regimens could be an important step toward addressing the current global challenges around TB treatment complexity, and the diagnosis and treatment of drug-resistant TB.
Normal dose moxifloxacin maintained effectiveness in rifampin-resistant TB (post)
A short, 9-month regimen of normal-dose moxifloxacin maintained good effectiveness up to 24 months after the cessation of therapy in patients with rifampicin-resistant tuberculosis (RR-TB), according to the results of an observational cohort study published in EClinicalMedicine.
PLOS Medicine Special Collection on Advances in Clinical Trial Design for Development of New Treatments for TB (post)
06 March 2020 | GENEVA -- A Special Collection on Advances in Clinical Trial Design for Development of New Treatments for Tuberculosis has been released by PLOS Medicine. This Special Collection, that is now complete with the publication of its last paper, contains a series of articles that articulate the essential new steps in clinical research that will pave the way for the development of future optimal treatment for all forms of tuberculosis. The Collection has been sponsored by the World Health Organization (WHO) and the French National Research Institute for Sustainable Development (IRD-France), and coordinated by Dr Christian Lienhardt, Research Director at IRD-France and Dr Payam Nahid, Professor at University of California, San Francisco, USA
Current and future treatments for TB (post)
A clinical review, published in The BMJ, summarized the current state of TB treatment with an emphasis on the ongoing clinical trials to anticipate how guidelines may change in the coming years.
TB drug delamanid fast drying out, India yet to receive new stocks from Japan (post)
Indian Government is now looking to buy delamanid for the first time from Otsuka.
RESIST-TB webinar: NiX-TB regimen for XDR-TB (post)
RESIST-TB will host a webinar on 26 March 2020 to discuss the recently published work on the NiX-TB trial, which focuses on treatment of extensively drug-resistant TB (XDR-TB).
CROI 2020 TB round up (post)
Treatment Action Group (TAG) released an overview of TB data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) virtually held on 8-11 March 2020. A summary of major findings, TAG’s take on them, and high-level summaries of select findings are available here.
MSF technical briefs (post)
Médecins Sans Frontières (MSF) updated two of its technical briefs, A rapid TB test for people living with HIV and Making the switch.
EMA panel backs pretomanid for drug-resistant TB (post)
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of pretomanid FGK (FGK Representative Service GmbH) for drug-resistant tuberculosis (TB).
Darunavir/ritonavir with rifampicin may be hepatotoxic (post)
Darunavir/ritonavir administered with rifampicin causes hepatotoxicities in people living with HIV, according to results of a study published in the Journal of Antimicrobial Chemotherapy.
Page 52 of 108 · Total posts: 0
←First 51 52 53 Last→